Company profile
ZyVersa Therapeutics, Inc. CIK 1859007
Ticker
ZVSA (OTC)
Industry
Pharmaceutical Preparations
Headquarters
Lighthouse Point, FL 33064
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
-$24.95M
Total assets
$347.9K
Total liabilities
$12.73M
Stockholders' equity
-$12.39M
Cash & equivalents
$101.8K
Operating income
-$25.49M
Operating cash flow
-$5.11M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-03-31. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
3,660.4%
Equity / assets
-3,560.4%
CapEx / revenue
—
Operating cash flow / net income
0.20×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
-$24.95M
$347.9K
$12.73M
-$12.39M
2024
—
-$9.41M
$20.60M
$12.08M
$8.52M
2023
—
-$98.30M
$22.11M
$11.04M
$11.07M
2022
—
—
$118.51M
$18.51M
$99.66M
2021
—
—
$77.14M
$3.65M
-$2.26M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-07-16
Financials filed via
Form 10-K
filed 2026-03-31
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Lighthouse Point, FL 33064
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:26 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.